Intellia Therapeutics

ISIN US45826J1051

WKN A2AG6H

Market cap (in EUR)

1,044 m

Country

United States

Sector

Healthcare

Dividend yield

0.00%

Overview

Quote

Description

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Show more Show less

Healthcare Biopharmaceuticals Other Biopharmaceuticals United States

Chart

Financials

Key metrics

Market capitalisation, EUR	1,044 m
EPS, EUR	-3.86
P/B ratio	1.6
P/E ratio	-
Dividend yield	0.00%

Income statement (2024)

Revenue, EUR	54 m
Net income, EUR	-480 m
Profit margin	-896.77%

What ETF is Intellia Therapeutics in?

There are 3 ETFs which contain Intellia Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Intellia Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).

ETF	Weight	Investment focus	Fund size (in m EUR)
Amundi MSCI Disruptive Technology UCITS ETF Acc	0.07%	Equity World Technology Social/Environmental Innovation	145
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	0.11%	Equity United States Health Care Biotech	46
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist)	0.02%	Equity United States Small Cap	182

Performance

Returns overview

YTD	+14.34%
1 month	+11.21%
3 months	-59.43%
6 months	-13.80%
1 year	-23.35%
3 years	-73.70%
5 years	-86.11%
Since inception (MAX)	-61.72%
2025	-31.31%
2024	-60.73%
2023	-11.25%
2022	-69.20%

Monthly returns in a heat map

Risk

Risk metrics in this section:

Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.

ETF returns include dividend payments (if applicable).